Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

What’s powering a $26.28 billion opportunity? The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood ...

Switzerland is a major exporter of drugs to the U.S., with pharmaceuticals accounting for almost half of Swiss goods exports to America in 2024.

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novartis AG, with a price target of CHF115.00. The company’s shares opened today at CHF96.53. Papadakis ...

See the latest Novartis AG Registered Shares stock price (NOVN:XSWX), related news, valuation, dividends and more to help you make your investing decisions.

See the latest Novartis AG ADR stock price (NVS:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- The antimetabolite drug market has been exhibiting strong growth in recent years, advancing from $9.31 billion in 2024 to an ...